infectious diseases
Pneumococcal Vaccine
Administration ofPneumococcal Vaccine
The usual dose of each vaccine is 0.5 mL IM for PCV20 0.5 mL IM for PCV13 0.5 mL IM for PCV15 0.5 mL IM or subcutaneous for PCSV23 People with asymptomatic or symptomatic HIV infection should be vaccinated as soon as possible after their diagnosis. Adults aged 19 to 64 years at highest risk of pneumococcal disease (eg, with functional or anatomic asplenia, chronic kidney disease, or another immunocompromising condition, including cancer and use of corticosteroids) should be given a second dose of PPSV23 5 years after the first PPSV23 dose. All people should be vaccinated with PPSV23 at age 65. If people were given 1 or 2 doses of PPSV23 before age 65 for any indication and ≥ 5 years have elapsed since their previous PPSV23 dose, they should be given another dose of the vaccine at age 65 or later. The second dose is given 5 years after the first (eg, at age 69 if the previous dose was given at age 64). Those who are given PPSV23 at or after age 65 should be given only 1 dose. When cancer chemotherapy or other immunosuppressive therapy is being considered, the interval between vaccination and initiation of immunosuppressive therapy should be ≥ 2 weeks. People should be not be vaccinated during chemotherapy or radiation therapy. For dosing schedules in children, seeCDC: Pneumococcal Vaccination: Summary of Who and When to VaccinateandCDC: Child and Adolescent Immunization Schedule by Age. 